Literature DB >> 19015493

Long-term effect of rituximab in anti-mag polyneuropathy.

L Benedetti1, C Briani, D Franciotta, M Carpo, L Padua, G Zara, R Zambello, M P Sormani, G L Mancardi, E Nobile-Orazio, A Schenone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19015493     DOI： 10.1212/01.wnl.0000335268.70325.33

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  20 in total

1.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

2.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

Review 3.  Update on therapy of chronic immune-mediated neuropathies.

Authors:  Chiara Briani; Dario Cocito; Marta Campagnolo; Pietro Emiliano Doneddu; Eduardo Nobile-Orazio
Journal:  Neurol Sci       Date:  2021-01-16       Impact factor: 3.307

Review 4.  Molecularly targeted therapies for dysimmune neuropathies.

Authors:  Andreas A Argyriou
Journal:  Mol Med       Date:  2009-05-05       Impact factor: 6.354

Review 5.  Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.

Authors:  Hafsa M Chaudhry; Michelle L Mauermann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2017-05       Impact factor: 7.616

6.  Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity.

Authors:  Michael A Maurer; Goran Rakocevic; Carol S Leung; Isaak Quast; Martin Lukačišin; Norbert Goebels; Christian Münz; Hedda Wardemann; Marinos Dalakas; Jan D Lünemann
Journal:  J Clin Invest       Date:  2012-03-19       Impact factor: 14.808

7.  Successful treatment of CANOMAD with IVIg and rituximab.

Authors:  Wolfgang N Löscher; Alexander Woertz; Monika Wallnöfer; Julia V Wanschitz; Gerhard Luef
Journal:  J Neurol       Date:  2013-02-12       Impact factor: 4.849

8.  Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.

Authors:  Jean-Marc Léger; Karine Viala; Guillaume Nicolas; Alain Créange; Jean-Michel Vallat; Jean Pouget; Pierre Clavelou; Christophe Vial; Andreas Steck; Lucile Musset; Benoit Marin
Journal:  Neurology       Date:  2013-05-10       Impact factor: 9.910

Review 9.  Advances in the Treatment of Paraproteinemic Neuropathy.

Authors:  Eduardo Nobile-Orazio; Mariangela Bianco; Andrea Nozza
Journal:  Curr Treat Options Neurol       Date:  2017-10-16       Impact factor: 3.598

Review 10.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

Authors:  Michael Pt Lunn; Eduardo Nobile-Orazio
Journal:  Cochrane Database Syst Rev       Date:  2016-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.